Evaluation of pharmaceutical care and quality of transitional care for COPD patients based on intelligent pharmaceutical care system: a randomized controlled clinical trial

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100053127

Enrollment

Unknown

Registered

2021-11-12

Start date

2021-11-30

Completion date

Unknown

Last updated

2022-09-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease

Interventions

Experimental group:Intelligent pharmaceutical care system transition care pharmaceutical care

Control group:Routine transitional care pharmaceutical care

Eligibility

Sex/Gender

All

Age

40 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.First diagnosis of COPD according to GLOD2021 guidelines; 2.Aged >= 40 years; 3.Except for COPD, no other advanced cancers (expected life cycle >= 6 months); 4.Agreed to follow up.

Exclusion criteria

Exclusion criteria: 1.According to the GINA2019 guidelines, combined with a diagnosis of asthma; 2.With severe cognitive impairment.

Design outcomes

Primary

Measure	Time frame
Readmission rate;	—

Countries

China

Contacts

Public ContactXiao Jian

Xiangya Hospital, Central South University

admanoas@163.com+86 13973168895

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026